Total Payments
$343,754
2024 Payments
$59,360
Companies
91
Transactions
1,078
Medicare Patients
49,866
Medicare Billing
$15.1M
Payment Breakdown by Category
Consulting$160,033 (46.6%)
Other$143,947 (41.9%)
Food & Beverage$16,544 (4.8%)
Travel$13,722 (4.0%)
Research$8,988 (2.6%)
Education$494.36 (0.1%)
Gifts$25.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $160,033 | 102 | 46.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,209 | 14 | 18.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $50,735 | 6 | 14.8% |
| Honoraria | $31,003 | 23 | 9.0% |
| Food and Beverage | $16,544 | 870 | 4.8% |
| Travel and Lodging | $13,722 | 29 | 4.0% |
| Unspecified | $8,988 | 11 | 2.6% |
| Education | $494.36 | 22 | 0.1% |
| Gift | $25.00 | 1 | 0.0% |
Payments by Type
General
$334,766
1,067 transactions
Research
$8,988
6 transactions
Ownership
$0
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $141,208 | 51 | $0 (2024) |
| Daiichi Sankyo Inc. | $86,254 | 86 | $0 (2024) |
| Amgen Inc. | $19,536 | 70 | $0 (2024) |
| OnMark, Inc. | $15,855 | 20 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $13,458 | 62 | $0 (2024) |
| Eli Lilly and Company | $6,153 | 2 | $0 (2020) |
| Heron Therapeutics, Inc. | $6,099 | 6 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $5,202 | 18 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $4,733 | 14 | $0 (2024) |
| Blueprint Medicines Corporation | $4,553 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,360 | 127 | Cornerstone Specialty Network LLC ($28,813) |
| 2023 | $119,445 | 184 | Cornerstone Specialty Network LLC ($56,969) |
| 2022 | $79,214 | 145 | Cornerstone Specialty Network LLC ($55,426) |
| 2021 | $24,369 | 95 | Daiichi Sankyo Inc. ($11,739) |
| 2020 | $34,473 | 134 | Daiichi Sankyo Inc. ($21,379) |
| 2019 | $2,376 | 143 | Janssen Pharmaceuticals, Inc ($254.60) |
| 2018 | $14,409 | 136 | Eli Lilly and Company ($6,053) |
| 2017 | $10,107 | 114 | Heron Therapeutics, Inc. ($4,786) |
All Payment Transactions
1,078 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $705.00 | General |
| 12/19/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: Oncology | ||||||
| 12/13/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $20.60 | General |
| 12/11/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $235.00 | General |
| 12/11/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $940.00 | General |
| 11/20/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $940.00 | General |
| 11/20/2024 | Cornerstone Specialty Network LLC | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 11/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Cornerstone Specialty Network LLC | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 11/17/2024 | Cornerstone Specialty Network LLC | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $9,933.00 | General |
| 11/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,675.00 | General |
| 11/17/2024 | Incyte Corporation | JAKAFI (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $18.24 | General |
| Category: Hematology/Oncology | ||||||
| 11/15/2024 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 11/13/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,410.00 | General |
| 11/12/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $24.42 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/29/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/28/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $13.49 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Cornerstone Specialty Network LLC | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 10/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $33.53 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Cornerstone Specialty Network LLC | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 STUDY OF LY2606368 IN PATIENTS WITH EXTENSIVE STAGE DISEASE SMALL CELL LUNG CANCER | Eli Lilly and Company | $6,053 | 1 |
| PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | PFIZER INC. | $2,835 | 4 |
| PHASE 1B STUDY OF LY3295668 ERBUMINE MONOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE, EXTENSIVE-STAGE SMALL-CELL LUNG CANCER | Eli Lilly and Company | $100.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 124 | 13,220 | 283,572 | $13.4M | $3.6M |
| 2022 | 118 | 12,602 | 263,293 | $10.8M | $3.2M |
| 2021 | 123 | 12,290 | 320,834 | $12.7M | $3.9M |
| 2020 | 116 | 11,754 | 322,938 | $14.0M | $4.4M |
Total Patients
49,866
Total Services
1,190,637
Medicare Billing
$15.1M
Procedure Codes
481
All Medicare Procedures & Services
481 procedure records from CMS Medicare Utilization — Page 1 of 20
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 53 | 28,800 | $4.0M | $1.2M | 28.9% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 26 | 23,520 | $1.9M | $556,784 | 29.6% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 221 | 420 | $1.3M | $425,746 | 33.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 70 | 9,060 | $362,400 | $167,609 | 46.2% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 29 | 4,370 | $371,450 | $167,405 | 45.1% |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 2023 | 24 | 3,280 | $557,600 | $111,593 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 255 | 780 | $195,000 | $98,566 | 50.5% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 257 | 484 | $350,900 | $86,895 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 419 | 789 | $157,900 | $68,343 | 43.3% |
| A9596 | Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | Office | 2023 | 11 | 66 | $175,000 | $68,208 | 39.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 292 | 758 | $219,820 | $66,609 | 30.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 214 | 412 | $206,000 | $64,537 | 31.3% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 13 | 1,910 | $238,750 | $46,539 | 19.5% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 246 | 484 | $290,400 | $38,144 | 13.1% |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | Office | 2023 | 15 | 3,280 | $442,800 | $33,739 | 7.6% |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 2023 | 18 | 360 | $306,000 | $32,185 | 10.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 800 | 2,341 | $93,640 | $24,167 | 25.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 36 | 4,209 | $105,225 | $23,431 | 22.3% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 15 | 22 | $66,000 | $22,370 | 33.9% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 34 | 3,152 | $69,344 | $19,518 | 28.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 840 | 2,564 | $76,920 | $19,347 | 25.2% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 70 | 110 | $165,000 | $16,395 | 9.9% |
| 83735 | Magnesium level | Office | 2023 | 763 | 2,201 | $55,025 | $14,364 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 89 | 89 | $31,150 | $14,066 | 45.2% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 760 | 2,181 | $54,525 | $12,825 | 23.5% |
About Dr. Eric Schaefer, M.D
Dr. Eric Schaefer, M.D is a Hematology & Oncology healthcare provider based in Fayetteville, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558325118.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Schaefer, M.D has received a total of $343,754 in payments from pharmaceutical and medical device companies, with $59,360 received in 2024. These payments were reported across 1,078 transactions from 91 companies. The most common payment nature is "Consulting Fee" ($160,033).
As a Medicare-enrolled provider, Schaefer has provided services to 49,866 Medicare beneficiaries, totaling 1,190,637 services with total Medicare billing of $15.1M. Data is available for 4 years (2020–2023), covering 481 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fayetteville, AR
- Active Since 04/12/2006
- Last Updated 03/30/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1558325118
Products in Payments
- Enhertu (Drug) $59,050
- CALQUENCE (Drug) $6,950
- ENHERTU (Drug) $5,364
- SUSTOL (Drug) $4,786
- Onivyde (Drug) $4,576
- ENHERTU (Biological) $3,406
- Optune (Device) $3,333
- Cabometyx (Drug) $2,892
- LORBRENA (Drug) $2,850
- INQOVI (Drug) $2,760
- AYVAKIT (Drug) $2,044
- SARCLISA (Biological) $2,039
- Tepmetko (Drug) $2,030
- LIBTAYO (Biological) $1,995
- Aliqopa (Drug) $1,767
- ZEPZELCA (Drug) $1,576
- GAVRETO (Drug) $1,501
- UKONIQ (Drug) $1,361
- HTX-011 (Drug) $1,300
- ADCETRIS (Biological) $1,252
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fayetteville
Trevor Feinstein, M.d, M.D
Hematology & Oncology — Payments: $293,737
Hematology & Oncology $293,737
Dr. J Beck, M.d., F.a.c.p, M.D., F.A.C.P
Hematology & Oncology — Payments: $181,928
Hematology & Oncology $181,928
Dr. Patrick Travis, M.d, M.D
Hematology & Oncology — Payments: $69,474
Hematology & Oncology $69,474
Dr. Stephan Rosenfeld, M.d, M.D
Hematology & Oncology — Payments: $63,644
Hematology & Oncology $63,644
Dr. Tariq Nazir, M.d, M.D
Hematology & Oncology — Payments: $60,775
Hematology & Oncology $60,775
Dr. Matthew Lockwood, Md, MD
Hematology & Oncology — Payments: $38,505
Hematology & Oncology $38,505